Compare ESQ & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | PCRX |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 1.0B |
| IPO Year | 2017 | 2010 |
| Metric | ESQ | PCRX |
|---|---|---|
| Price | $105.62 | $23.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $120.33 | $30.25 |
| AVG Volume (30 Days) | 99.5K | ★ 513.2K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | 14.20 | ★ 107.44 |
| EPS | ★ 1.40 | 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $35.15 | $6.78 |
| Revenue Next Year | $39.09 | $8.54 |
| P/E Ratio | ★ $74.65 | $330.36 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $87.54 | $18.80 |
| 52 Week High | $119.86 | $27.64 |
| Indicator | ESQ | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 47.56 |
| Support Level | $104.58 | $20.15 |
| Resistance Level | $105.65 | $24.20 |
| Average True Range (ATR) | 2.46 | 1.27 |
| MACD | -0.38 | -0.24 |
| Stochastic Oscillator | 12.93 | 25.80 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.